（文章来源：证券日报） 证券日报网讯 2月4日，昆药集团在互动平台回答投资者提问时表示，上市公司股价在二级市场的走势 及波动也受到包括行业政策在内的多重因素影响，敬请投资者注意投资风险。公司管理层始终高度专注 自身的经营管理，致力提升公司内在价值以回报广大投资者；同时，公司也通过多渠道、多方面与投资 者保持良性互动，积极向市场传递公司投资价值。 ...

证券日报网讯2月4日，昆药集团（600422）在互动平台回答投资者提问时表示，根据法律法规及监管要 求，公司的经营业绩情况将在法定披露渠道依法依规予以披露，敬请关注公司公告。 ...

Group 1 - The company, Kunming Pharmaceutical Group, stated that it strictly adheres to laws, regulations, and regulatory requirements, and will fulfill information disclosure obligations in a timely manner if any matters meet the disclosure standards [2] - The stock price fluctuations of the listed company are influenced by multiple factors, including macroeconomic conditions, industry cycles, and market sentiment [2]

证券日报网讯 1月27日，昆药集团在互动平台回答投资者提问时表示，昆药集团财务共享中心成立于 2021年，整体运行成熟、稳定。 （文章来源：证券日报） ...

证券日报网讯1月21日，昆药集团（600422）在互动平台回答投资者提问时表示，公司严格遵守法律法 规及监管要求，切实履行信息披露义务。如公司有应披露的信息，将及时依法予以公告，敬请关注公司 公告。 ...

Group 1 - The core viewpoint of the article is that Kunming Pharmaceutical Group has confirmed its normal operating status and stated that there are no undisclosed significant matters [2] Group 2 - The company responded to investor inquiries on its interactive platform [2] - The statement indicates transparency and confidence in the company's current business operations [2] - The company reassured investors that it is not facing any undisclosed issues that could impact its performance [2]

Group 1 - The core viewpoint of the article is that Kunming Pharmaceutical Group is currently operating normally and is focused on enhancing its intrinsic value despite stock price fluctuations influenced by macroeconomic factors, industry cycles, and market sentiment [1] - The company management emphasizes the importance of addressing investor concerns and is committed to the strategic goal of becoming a leader in the "silver-haired health industry" [1] - The company is working on deepening business integration and strengthening operational management to continuously enhance its core competitiveness and long-term investment value [1]

Core Viewpoint - The company emphasizes the importance of brand building and consumer trust for its Xuesaitong series products, focusing on a systematic upgrade from cultivation to manufacturing and branding [1] Group 1: Brand Development - The company is committed to enhancing the brand of the Xuesaitong series products through systematic upgrades [1] - It aims to strengthen consumer trust by focusing on the entire supply chain from cultivation to end branding [1] Group 2: Marketing Strategy - The company is establishing a high-quality team with both pharmaceutical expertise and marketing experience [1] - It is developing a multi-channel, multi-model marketing strategy to promote the Xuesaitong series products [1] - The company is continuously pushing for the transformation and upgrade of its marketing model [1] Group 3: Target Market - The company is focusing on the brand advantage of the "777" series in chronic disease management, particularly in the aging health sector [1]

Core Viewpoint - Kunming Pharmaceutical Group (600422) emphasizes the unique advantages of its core product, Xuesaitong soft capsules, which offer faster absorption rates and simplified formulations, enhancing product safety and differentiation [1] Product Development - The company is exploring the application of Xuesaitong soft capsules in precise indications and in combination with other medications, particularly the "Ali Therapy" which combines Xuesaitong soft capsules with aspirin, yielding positive academic results [1] - The company is committed to continuous technical iteration and upgrade research on existing products to meet the medication needs of different patient groups, thereby strengthening and enhancing long-term competitiveness [1] Patient-Centric Approach - The company places high importance on the medication experience and needs of various patient groups, offering alternative formulations such as Xuesaitong granules and Xuesaitong drops, with a reminder for patients to follow medical advice regarding usage [1]

Core Viewpoint - The traditional Chinese medicine sector experienced a decline of 0.71% on January 14, with Wanbangde leading the drop, while the Shanghai Composite Index fell by 0.31% and the Shenzhen Component Index rose by 0.56% [1] Group 1: Market Performance - The closing price of Wanbangde was 16.76, down by 3.01%, with a trading volume of 266,800 shares and a transaction amount of 450 million [2] - The top gainers in the traditional Chinese medicine sector included Renhe Pharmaceutical, which closed at 6.32, up by 3.10%, with a trading volume of 925,100 shares and a transaction amount of 579 million [1] - The overall net outflow of main funds in the traditional Chinese medicine sector was 342 million, while retail investors saw a net inflow of 240 million [2] Group 2: Individual Stock Analysis - Renhe Pharmaceutical had a net inflow of 74.86 million from main funds, accounting for 12.92% of its total, while retail investors had a net outflow of 50.46 million [3] - Kunming Pharmaceutical saw a net inflow of 44.97 million from main funds, representing 17.50%, with a net outflow of 28.44 million from retail investors [3] - Yunnan Baiyao had a net inflow of 22.29 million from main funds, which is 3.32% of its total, while retail investors experienced a net outflow of 25.09 million [3]